NEW YORK (GenomeWeb) – Investment bank Leerink Partners today said it has downgraded Bruker's stock to Market Perform from Outperform based on expectations that margin expansion will be more difficult than is indicated by the current stock price.

Bruker's stock has appreciated 55 percent in the past year compared to no appreciation for the S&P 500, wrote Leerink analyst Dan Leonard in his note today. Leerink believes "the large, discrete activities for margin expansion are in the rear view mirror," he added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.